drugset
drugset / Trial / NCT02141399

A Long-Term Safety Study of ALKS 5461

NCT02141399 ↗

Phase 3 Completed 1485 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.

Timeline

Start
2014-05
Primary completion
2017-11-20
Completion
2017-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown — Other

Indications

major depressive disorder